Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fitusiran→

Fitusiran Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1499251-18-1
Molecular formula
C520H679F21N175O309P43S6
Molecular weight
16248.27 g/mol
Drug class
Antithrombin-directed small interfering RNA (siRNA)RNA interference haemostatic therapy
Mechanism of action
A GalNAc-conjugated siRNA is taken up by hepatocytes and directs RNA-induced silencing complex-mediated degradation of antithrombin mRNA, reducing antithrombin protein and increasing thrombin generation to improve haemostasis.
Indications / reported uses
  • Routine prophylaxis to prevent or reduce bleeding episodes in adults and paediatric patients aged 12 years and older with haemophilia A or B, with or without factor VIII or IX inhibitors, under the US QFITLIA indication; subcutaneous dosing is monitored using antithrombin activity

Sources: US DailyMed — QFITLIA (fitusiran), label updated 15 September 2025 · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Antithrombin-directed small interfering RNA (siRNA); RNA interference haemostatic therapy

Mechanism of action

A GalNAc-conjugated siRNA is taken up by hepatocytes and directs RNA-induced silencing complex-mediated degradation of antithrombin mRNA, reducing antithrombin protein and increasing thrombin generation to improve haemostasis.

General use cases

  • Routine prophylaxis to prevent or reduce bleeding episodes in adults and paediatric patients aged 12 years and older with haemophilia A or B, with or without factor VIII or IX inhibitors, under the US QFITLIA indication; subcutaneous dosing is monitored using antithrombin activity

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Fitusiran Environmental Risk Assessment (ERA) (the Fitusiran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.